Ayati Devices has raised Rs 15 crore (about $1.5 million) in a Pre-Series A funding round led by Inflexor Ventures. The Bengaluru-based medical technology startup will use the capital to accelerate commercialisation, expand in domestic and international markets, strengthen manufacturing, and invest more in research and artificial intelligence.
The round marks a step up for the startup as it moves from clinical validation to commercial growth.
Founded in 2019 by Nishant Kathpal, Ayati Devices builds portable, point-of-care diagnostic devices for diabetic foot complications and peripheral vascular disease. The startup was incubated at IIT Bombay’s SINE and aims to make early screening accessible beyond tertiary hospitals.
Read More: AI Startup Discovered Materials Raises $9 Million to Speed Up Chip Material Discovery
Early screening, beyond big hospitals
In India, diabetic foot complications are a major cause of hospitalisation, and many cases are detected late.
Read More: Bakingo Raises Rs 100 Cr at 2.6X Higher Valuation in Series B
Diabetic foot problems often begin with changes in nerve function, blood flow and tissue perfusion. Catching them early can stop small issues from becoming severe. Ayati’s platform brings these assessments together in one range of products.
Its portfolio includes Vibrasense, which measures vibration perception threshold to screen large-fibre peripheral neuropathy. Vibrasense+T adds warm and cold perception testing. Vasosense screens for peripheral artery disease, while Angiocam offers real-time tissue perfusion imaging.
The company also offers the PODIA Trolley, a pay-per-test model that cuts the upfront investment healthcare providers need. The model helps smaller clinics and diagnostic centres offer screening without heavy equipment costs.
30 countries, 1 million screenings
Ayati said its devices are deployed across 30 countries, with more than 10,000 units in the field. Its solutions have enabled over 1 million screenings, with clinical deployments at leading institutions and partners across India and abroad.
The startup’s clinical work includes a study of 562 people with type 2 diabetes. The results support Vibrasense as a portable, low-cost alternative to bulky lab equipment.
Vibrasense testing was compared with conventional biothesiometry and nerve conduction studies for screening diabetic peripheral neuropathy.
What the fresh capital changes
The round gives Ayati room to move from deployment to larger commercial expansion. Manufacturing is a priority, along with deeper investment in research and artificial intelligence for diagnostic workflows.
Why it matters
Diabetic foot complications are a growing burden in India, where millions live with diabetes and screening reach is limited. A portable device that works beyond big hospitals can change how early detection happens. Ayati now has the capital and the track record to push that change across more markets.